Initial therapeutic management
| All | Young (<65 years) | Elderly (65–74 years) | Very elderly (≥75 years) | p-value | |
| Patients | 248 (100) | 101 (40.7) | 82 (33.1) | 65 (26.2) | |
| Endothelin receptor antagonists | 116 (46.8) | 59 (58.4) | 28 (34.1) | 29 (44.6) | 0.005 |
| Phosphodiesterase type 5 inhibitors | 122 (49.2) | 46 (44.6) | 43 (52.4) | 33 (50.8) | 0.632 |
| Epoprostenol | 14 (5.6) | 11 (10.9) | 1 (1.2) | 2 (3.1) | 0.014 |
| Calcium channel blockers | 8 (3.2) | 3 (3) | 5 (6.1) | 0.120 | |
| Guanylate cyclase stimulators | 2 (0.8) | 1 (1.2) | 1 (1.5) | 0.515 | |
| Medication regimens | 0.010 | ||||
| Therapeutic abstention | 37 (14.9) | 15 (14.9) | 10 (12.2) | 12 (18.5) | |
| Monotherapy | 164 (66.1) | 58 (57.4) | 65 (79.3) | 41 (63.1) | |
| Dual therapy | 42 (16.9) | 23 (22.8) | 7 (8.5) | 12 (18.5) | |
| Triple therapy | 5 (2.0) | 5 (5.0) |
Data are presented as n (%), unless otherwise stated.